Captixbio is excited to announce Mr Duncan Thomson as our new CEO. Duncan takes over from former CEO Helen Wray as she continues to work

Captixbio is delighted to welcome Professor Martina Stenzel to its Scientific & Clinical Advisory Panel. With a career spanning over 20 years focusing on polymer

Captixbio’s CEO Helen Wray recently sat down with CRIISP Media to talk all things Impact Investing, highlighting the company’s ‘for purpose, for profit’ mantra and

Captixbio’s partner, SVI, are leading a new clinical trial – The BANDIT Trial – which will test the effectiveness of the drug, baricitinib, in stopping

Observational data of a Fremantle community study presented by Timothy Davis, of the University of Western Australia, at the 56th European Association for the Study

Captixbio is thrilled to learn of the new $47 million Targeted Translation Research Accelerator (TTRA) initiative provided by the Federal Government to fast-track new treatments

Wholesale Investor Health, Med & Technology Virtual Showcase that will launch online at 12 noon on Friday, 3rd July, 2020

COVID-19 is of great concern across all our communities in Australia and overseas. JDRF Australia has published comment on recent academic research just starting to emerge…

Captixbio is the grateful beneficiary of a second CSIRO Kickstart grant to support its ongoing collaborative program with CSIRO’s Biomedical Manufacturing research group.

JDRF-funded study throws new light on real cost of Type 1 Diabetes.